(ABEO) Abeona Therapeutics - Ratings and Ratios

Abeona Therapeutics Inc. (NASDAQ:ABEO) is a clinical-stage biopharmaceutical company specializing in gene and cell therapies for severe genetic disorders. Its lead program, EB-101, is an autologous, engineered cell therapy currently in Phase III trials for recessive dystrophic epidermolysis bullosa (RDEB), a rare skin disorder causing severe blistering. The company is also developing ABO-503 for X-linked retinoschisis, a condition leading to vision loss in males, and ABO-504 for Stargardt disease, an inherited juvenile macular degeneration. Additionally, ABO-505 targets autosomal dominant optic atrophy, a progressive vision disorder. Abeonas proprietary AIM vector platform enhances AAV-based gene therapy delivery, potentially improving efficacy for various genetic diseases. Formerly known as PlasmaTech Biopharmaceuticals, the company rebranded as Abeona Therapeutics in 2015 and is based in Cleveland, Ohio.

Based on and , the three-month forecast for ABEO indicates a potential price decline. The SMA-20 of 5.68 and SMA-50 of 5.61 suggest resistance levels above the current price of 5.24, possibly leading to a downtrend. The ATR of 0.25 signals moderate volatility, expected to rise slightly. Fundamental analysis shows a market cap of $224.07M with a P/B ratio of 4.88, indicating moderate valuation. The P/S ratio of 61.63 reflects high revenue per share relative to price. Overall, ABEO is expected to face headwinds, with a target price range of $4.80 to $5.00 and increased volatility of $0.30 to $0.35 over the next three months.